COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 503 participants.

Also called NCT05734690

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 503 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05734690
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05734690. Randomized; no masking; primary purpose treatment. Start 2023-05-05 (actual); primary completion 2025-05-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
Acronym
COPILOT-HF
Condition
Heart Failure
Intervention (Drug)
SGLT2i, beta blocker, ARNI, MRA, MTD
Intervention (Behavioral)
Education-First
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05734690
Content hash
979c25d6655c3e3c684fd1827f1e2535432a1904dc19df732141b00bb7ab5738